期刊
CELLS
卷 11, 期 19, 页码 -出版社
MDPI
DOI: 10.3390/cells11193028
关键词
antigen-presenting cells; dendritic cells; monocytes; immunotherapy; cancer
类别
资金
- Translational Molecular Pathology-Immunoprofiling platform (TMP-IL) at the Department of Translational Molecular Pathology
- University of Texas MD Anderson Cancer
- National Cancer Institute (NCI) [U24CA224285]
Dendritic cells (DCs) are crucial in immunology, yet targeting them remains challenging. Understanding and utilizing dendritic cells can lead to new therapeutic strategies in cancer treatment.
Dendritic cells (DCs) are a unique myeloid cell lineage that play a central role in the priming of the adaptive immune response. As such, they are an attractive target for immune oncology based therapeutic approaches. However, targeting these cells has proven challenging with many studies proving inconclusive or of no benefit in a clinical trial setting. In this review, we highlight the known and unknown about this rare but powerful immune cell. As technologies have expanded our understanding of the complexity of DC development, subsets and response features, we are now left to apply this knowledge to the design of new therapeutic strategies in cancer. We propose that utilization of these technologies through a multiomics approach will allow for an improved directed targeting of DCs in a clinical trial setting. In addition, the DC research community should consider a consensus on subset nomenclature to distinguish new subsets from functional or phenotypic changes in response to their environment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据